Yüklüyor......
Challenges of driving CD30-directed CAR-T cells to the clinic
Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19. CD3...
Kaydedildi:
| Yayımlandı: | BMC Cancer |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6404322/ https://ncbi.nlm.nih.gov/pubmed/30841880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5415-9 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|